What are the indications, dosing regimen, contraindications, and side effects of Ocupol (polymyxin B and chloramphenicol) ophthalmic ointment?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 1, 2026 • View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Ocupol (Polymyxin B + Chloramphenicol) Ophthalmic Ointment: Clinical Uses and Guidelines

Primary Indication

Ocupol ointment is indicated for bacterial conjunctivitis, where it provides effective treatment comparable to other topical antibiotics, but it should NOT be used as primary therapy for bacterial keratitis due to inadequate corneal penetration. 1

Specific Clinical Uses

Bacterial Conjunctivitis

  • Standard dosing: Apply to the affected eye(s) 4 times daily for 7 days 2, 3
  • The combination demonstrates clinical efficacy equivalent to chloramphenicol alone in treating bacterial conjunctivitis, with both treatments showing no statistically significant differences in organism eradication or clinical improvement 2, 3
  • Effective against common pathogens including Haemophilus influenzae, Staphylococcus aureus, Streptococcus pneumoniae, and Pseudomonas aeruginosa 3

Adjunctive Therapy for Mild Keratitis

  • May be used at bedtime only as adjunctive therapy in less severe bacterial keratitis cases, but never as monotherapy 4, 1
  • Ointments lack sufficient solubility to achieve therapeutic corneal penetration required for optimal treatment of keratitis 4

Corneal Abrasion Prophylaxis

  • Chloramphenicol 1% ointment applied 3 times daily for 3 days effectively prevents bacterial keratitis following corneal abrasions when initiated within 24 hours of injury 1

Dosing Regimen

  • Bacterial conjunctivitis: Apply a thin ribbon of ointment to the lower conjunctival sac 4 times daily for 7 days 2, 3
  • Alternative shorter course: 3 times daily for 5 days has also been studied with comparable efficacy 3
  • Patients should show reduced discharge, pain, and lid edema within 24-48 hours; if no improvement occurs, consider switching to a fluoroquinolone or obtaining cultures 1

Important Contraindications and Limitations

Absolute Contraindications

  • Severe bacterial keratitis: Requires fortified topical antibiotics or fluoroquinolones with intensive loading doses (every 5-15 minutes initially, then hourly) 4, 1
  • Contact lens-related infections: Fluoroquinolones are strongly preferred due to superior Pseudomonas aeruginosa coverage 1
  • Gonococcal or chlamydial conjunctivitis: Requires systemic antibiotic therapy (ceftriaxone for gonorrhea, azithromycin or doxycycline for chlamydia) 1
  • Fungal or mycobacterial ocular infections: Polymyxin-chloramphenicol has no activity against these pathogens 1

Relative Contraindications

  • Lesions close to the limbus: May require systemic antibiotics in addition to topical therapy 1
  • Neonatal ocular prophylaxis: Erythromycin 0.5% ointment is the only FDA-approved agent for this indication in the United States 5

Common Side Effects and Safety Profile

  • Both polymyxin B and chloramphenicol ophthalmic ointments are generally well tolerated with minimal adverse reactions reported in clinical trials 2, 6, 3, 7
  • Prolonged use beyond 10 days can cause medication toxicity and corneal epithelial damage 1
  • Avoid tapering below 3-4 times daily before completing the full course, as subtherapeutic dosing increases antimicrobial resistance risk 1

Clinical Pearls and Pitfalls

When to Choose Fluoroquinolones Instead

  • Faster symptom resolution: Moxifloxacin 0.5% three times daily achieves complete resolution in 81% of patients by 48 hours versus 44% with polymyxin/trimethoprim (P = 0.001) 8
  • Superior for keratitis: Topical fluoroquinolones achieve better tissue penetration and broader coverage than polymyxin-based combinations 1
  • Contact lens wearers: Always use fluoroquinolones due to enhanced Pseudomonas risk 1

Monitoring and Follow-Up

  • Expect clinical improvement within 24-48 hours; lack of response warrants culture and sensitivity testing with consideration of fluoroquinolone escalation 1
  • For patients with chronic epithelial defects or severe tear deficiency, prophylactic antibiotics remain controversial due to risk of promoting resistant organisms 4

References

1
Guideline

Treatment of Bacterial Conjunctivitis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

4
Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

5
Guideline

CDC Recommendations for Neonatal Ocular Prophylaxis with Erythromycin

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Related Questions

What is the proper dosing schedule, administration technique, and precautions for polymyxin B ophthalmic drops in treating confirmed bacterial conjunctivitis (pink eye) in a patient without a polymyxin allergy?
What eye drops contain polymyxin B?
What is the recommended dosing schedule for Polytrim (polymyxin B 0.1%/trimethoprim 0.025%) ophthalmic solution in bacterial conjunctivitis?
What is the recommended dosing for Polymyxin B (Polymyxin B)-Trimethoprim (Trimethoprim) Ophthalmic Solution for a patient with bacterial conjunctivitis?
What inexpensive eye drop is appropriate for treating acute bacterial conjunctivitis?
What low‑cost diagnostic and management options can I use for a 56‑year‑old woman with uncontrolled diabetes, hand and ankle swelling, chronic hand pain, fatigue, hunger, and anxiety who declines imaging, laboratory tests, and home glucose monitoring due to financial constraints?
When should maintenance chemotherapy be initiated after completing the fourth cycle, assuming recovery from acute toxicities and evidence of stable disease or response?
What is the appropriate second‑line maintenance therapy for a patient with advanced non‑small cell lung cancer who has completed 4‑6 cycles of platinum‑based induction chemotherapy, has stable disease and recovered from toxicities, and whose tumor is non‑squamous without EGFR mutation, squamous, or EGFR‑mutated?
What is the recommended first‑line therapy for an uncomplicated urinary tract infection in an otherwise healthy, non‑pregnant adult woman without structural abnormalities, recent instrumentation, diabetes, immunosuppression, or other risk factors?
How should I manage a patient with acute decompensated heart failure, elevated B-type natriuretic peptide, severe hyponatremia, and impaired renal function?
In an elderly patient with Waldenström macroglobulinemia (lymphoplasmacytic lymphoma) producing immunoglobulin G, a free light‑chain kappa/lambda ratio of 0.03 and beta‑2 microglobulin of 2.9 mg/L, who has received venetoclax 800 mg daily for three months, when should I expect the laboratory values to begin improving?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question